Jazz Extraordinary Items vs Non Recurring Analysis
JAZZ Stock | USD 108.99 1.50 1.36% |
Jazz Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Jazz Pharmaceuticals PLC recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Jazz Pharmaceuticals PLC is a good investment. Please check the relationship between Jazz Pharmaceuticals Extraordinary Items and its Non Recurring accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jazz Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
Extraordinary Items vs Non Recurring
Extraordinary Items vs Non Recurring Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Jazz Pharmaceuticals PLC Extraordinary Items account and Non Recurring. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Jazz Pharmaceuticals' Extraordinary Items and Non Recurring is -0.65. Overlapping area represents the amount of variation of Extraordinary Items that can explain the historical movement of Non Recurring in the same time period over historical financial statements of Jazz Pharmaceuticals PLC, assuming nothing else is changed. The correlation between historical values of Jazz Pharmaceuticals' Extraordinary Items and Non Recurring is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Extraordinary Items of Jazz Pharmaceuticals PLC are associated (or correlated) with its Non Recurring. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Recurring has no effect on the direction of Extraordinary Items i.e., Jazz Pharmaceuticals' Extraordinary Items and Non Recurring go up and down completely randomly.
Correlation Coefficient | -0.65 |
Relationship Direction | Negative |
Relationship Strength | Weak |
Extraordinary Items
Non Recurring
Most indicators from Jazz Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Jazz Pharmaceuticals PLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jazz Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Selling General Administrative is likely to rise to about 1.4 B in 2024, despite the fact that Tax Provision is likely to grow to (177.5 M).
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 2.7B | 3.1B | 2.8B | 2.9B | Total Revenue | 3.1B | 3.7B | 3.8B | 4.0B |
Jazz Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Jazz Pharmaceuticals Account Relationship Matchups
Jazz Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Common Stock Shares Outstanding | 57.6M | 56.5M | 59.7M | 62.5M | 72.1M | 51.5M | |
Total Assets | 5.5B | 6.5B | 12.3B | 10.8B | 11.4B | 12.0B | |
Short Long Term Debt Total | 1.8B | 2.2B | 6.1B | 5.8B | 5.8B | 6.1B | |
Other Current Liab | 278.8M | 377.9M | 675.9M | 811.0M | 774.5M | 813.2M | |
Total Current Liabilities | 364.5M | 653.7M | 809.3M | 933.2M | 1.5B | 1.6B | |
Total Stockholder Equity | 3.1B | 3.7B | 4.0B | 3.1B | 3.7B | 3.9B | |
Other Liab | 337.7M | 233.9M | 1.4B | 1.0B | 1.2B | 1.3B | |
Property Plant And Equipment Net | 270.9M | 257.1M | 343.4M | 301.4M | 235.0M | 119.6M | |
Net Debt | 1.1B | 1.2B | 5.5B | 4.9B | 4.6B | 4.8B | |
Retained Earnings | 1.1B | 1.2B | 830.2M | 733.6M | 878.7M | 922.6M | |
Accounts Payable | 47.5M | 26.9M | 100.3M | 90.8M | 102.8M | 107.9M | |
Cash | 637.3M | 1.1B | 591.4M | 881.5M | 1.2B | 1.3B | |
Non Current Assets Total | 3.9B | 3.7B | 9.7B | 8.2B | 8.1B | 8.5B | |
Non Currrent Assets Other | 47.9M | 25.7M | 40.8M | 58.9M | 240.7M | 252.8M | |
Other Assets | 272.2M | 415.0M | 363.9M | 435.1M | 500.4M | 525.4M | |
Long Term Debt | 1.6B | 1.8B | 6.0B | 5.7B | 5.1B | 5.4B | |
Cash And Short Term Investments | 1.1B | 2.1B | 591.4M | 881.5M | 1.6B | 1.7B | |
Net Receivables | 356.0M | 396.5M | 563.4M | 651.5M | 705.8M | 741.1M | |
Good Will | 920.0M | 958.3M | 1.8B | 1.7B | 1.8B | 1.8B | |
Short Term Investments | 515M | 440M | 1.1B | 30M | 420M | 441M | |
Liabilities And Stockholders Equity | 5.5B | 6.5B | 12.3B | 10.8B | 11.4B | 12.0B | |
Non Current Liabilities Total | 2.1B | 2.2B | 7.5B | 6.8B | 6.1B | 6.4B | |
Inventory | 78.6M | 95.4M | 1.1B | 714.1M | 597.0M | 626.9M | |
Other Current Assets | 78.9M | 152.5M | 252.4M | 267.2M | 334.8M | 351.5M | |
Other Stockholder Equity | 2.3B | 2.6B | 3.5B | 3.5B | 3.7B | 3.9B | |
Total Liab | 2.4B | 2.9B | 8.3B | 7.7B | 7.7B | 8.0B | |
Property Plant And Equipment Gross | 270.9M | 257.1M | 343.4M | 301.4M | 368.3M | 386.8M | |
Total Current Assets | 1.6B | 2.8B | 2.6B | 2.6B | 3.3B | 3.4B | |
Accumulated Other Comprehensive Income | (223.4M) | (134.4M) | (400.4M) | (1.1B) | (841.7M) | (799.6M) | |
Intangible Assets | 2.4B | 2.2B | 7.2B | 5.8B | 5.4B | 5.7B | |
Property Plant Equipment | 270.9M | 127.9M | 343.4M | 301.4M | 346.6M | 363.9M | |
Current Deferred Revenue | 4.7M | 2.5M | 2.1M | 463K | 35.1M | 36.8M | |
Net Tangible Assets | (250.0M) | 648.7M | (5.0B) | (4.3B) | (3.9B) | (3.7B) | |
Capital Surpluse | 2.3B | 2.6B | 3.5B | 3.5B | 4.0B | 2.2B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Jazz Pharmaceuticals PLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Jazz Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Jazz Pharmaceuticals Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Jazz Pharmaceuticals Plc Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jazz Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Jazz Pharmaceuticals PLC information on this page should be used as a complementary analysis to other Jazz Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Complementary Tools for Jazz Stock analysis
When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Stocks Directory Find actively traded stocks across global markets | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
Is Jazz Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Jazz Pharmaceuticals. If investors know Jazz will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Jazz Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.757 | Earnings Share 4.83 | Revenue Per Share 60.956 | Quarterly Revenue Growth 0.01 | Return On Assets 0.0407 |
The market value of Jazz Pharmaceuticals PLC is measured differently than its book value, which is the value of Jazz that is recorded on the company's balance sheet. Investors also form their own opinion of Jazz Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Jazz Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Jazz Pharmaceuticals' market value can be influenced by many factors that don't directly affect Jazz Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Jazz Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Jazz Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Jazz Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.